Hormonal Therapy for Transgender Patients

Hormonal Therapy: Goals & Assessment - Setting the Stage

Primary Goals:

• Align physical characteristics with gender identity.
  • Induce affirmed gender's secondary sex characteristics.
  • Suppress natal sex characteristics.
• Improve mental health & quality of life.
• Maintain hormone levels in physiologic range of affirmed gender.

Initial Assessment Protocol:

• Eligibility Criteria:
  • Persistent, well-documented gender dysphoria.
  • Capacity for informed consent.
  • Age of majority (or specific criteria for minors).
  • Address significant co-existing medical/mental health conditions.
• Baseline Evaluation:
  • Detailed history (medical, surgical, psychiatric).
  • Physical examination.
  • Labs: Hormones (testosterone, estradiol, LH, FSH, prolactin), CBC, LFTs, lipids, HbA1c.
• Essential Counseling:
  • Realistic outcomes & timeline.
  • Potential risks (e.g., VTE, metabolic changes) & benefits.
  • Crucial: Fertility preservation options before starting hormones.
  • Irreversible vs. reversible effects.
  • Lifelong monitoring necessity.

⭐ WPATH SOC 8 provides comprehensive guidelines for gender-affirming care, including criteria for hormone therapy initiation.

Feminizing Therapy (AMAB) - Graceful Gendershifting

• Goal: Induce female secondary sex characteristics (breast growth, fat redistribution); suppress male ones (↓testosterone).
• Primary Regimens: Estrogen + Anti-androgen.
  • Estrogens:
    • Estradiol: Oral (1-8 mg/day), transdermal patch (50-200 mcg/twice weekly), parenteral.
    • Target serum estradiol: 100-200 pg/mL.
    • ⚠️ Avoid Ethinyl Estradiol (↑ VTE risk).
  • Anti-androgens (Target T <50 ng/dL):
    • Spironolactone: 100-300 mg/day. (📌 Monitor K+!)
    • Cyproterone Acetate (CPA): 10-25 mg/day. (Monitor LFTs, prolactin).
    • GnRH Agonists (e.g., Leuprolide): Most potent, costly.
• Monitoring: Baseline, then q3 months for 1st yr, then 1-2x/yr. Includes hormones, K+ (spiro), LFTs, prolactin, lipids.
• Key Effects Timeline:
  • Breast development: 3-6 mo (max 2-3 yrs).
  • Body fat redistribution: 3-6 mo (max 2-5 yrs).
• Major Risks: VTE (↓ with transdermal estradiol), hyperprolactinemia, gallstones.

⭐ Transdermal estradiol preferred over oral, esp. >40 yrs or VTE risk factors (favorable risk profile). oka

Masculinizing Therapy (AFAB) - Powering Potency

• Goal: Induce virilization; suppress menses & female secondary characteristics.
• Primary Agent: Testosterone.
  • Formulations:
    • Injectable (cypionate, enanthate): IM/SC q 1-4 wks. Common.
    • Transdermal (gel, patch): Daily. Stable levels.
    • Oral (undecanoate): Safer than older oral alkylated androgens.
    • Implants (pellets): Subdermal, long-acting (3-6 months).
• Key Effects & Onset: 📌 Voice deepening (3-12m, irreversible), Hirsutism (3-6m), Clitoromegaly (3-9m, irreversible), Menstrual cessation (2-6m), Muscle mass ↑, fat redistribution.
• Monitoring:
  • Baseline: LFTs, lipid profile, Hb/Hct.
  • Regularly: Serum testosterone (aim for male physiologic range; check trough for injectables), estradiol, LFTs, lipids, Hb/Hct.
• Critical Risks & Management:
  • Erythrocytosis: Monitor Hct (risk >50-54%). Dose ↓ or phlebotomy if needed.
  • Hepatotoxicity: Rare with non-alkylated oral/parenteral forms.
  • Dyslipidemia: Monitor (↑LDL, ↓HDL). Manage PRN.
  • Acne, androgenetic alopecia.
  • Fertility: Counsel on oocyte cryopreservation pre-therapy.

⭐ Target testosterone levels are within the physiologic male range; monitor for erythrocytosis (Hct >52-54% often requires dose adjustment or phlebotomy).

High‑Yield Points - ⚡ Biggest Takeaways

• Feminizing therapy: Estrogen plus anti-androgens (e.g., spironolactone, GnRH analogs).
• Masculinizing therapy: Primarily testosterone administration.
• Goals: Suppress natal hormones; induce desired secondary sexual characteristics.
• Monitoring: Essential for efficacy, hormone levels, lipids, LFTs, VTE (estrogen), polycythemia (testosterone).
• Fertility preservation discussion is vital prior to therapy.
• Note irreversible effects: voice (testosterone), breast development (estrogen).
• Key contraindications: Hormone-sensitive malignancies, high VTE risk, severe liver disease.